Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in Net LoansChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Capital Expenditures (2022 - 2023)

Abvc Biopharma (ABVC) has disclosed Capital Expenditures for 3 consecutive years, with -$419374.0 as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Capital Expenditures fell 9725.29% year-over-year to -$419374.0, compared with a TTM value of -$414928.0 through Dec 2023, down 446.66%, and an annual FY2023 reading of $21201.0, down 82.29% over the prior year.
  • Capital Expenditures was -$419374.0 for Q3 2023 at Abvc Biopharma, down from $89.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $93220.0 in Q1 2022 and bottomed at -$419374.0 in Q3 2023.